2. Search Result
Search Result
Results for "

FGFR4+inhibitor

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

1

Biochemical Assay Reagents

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100492
    Fisogatinib
    5 Publications Verification

    BLU-554

    		 FGFR Cancer
    Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling .
    Fisogatinib
  • HY-12823
    BLU9931
    Maximum Cited Publications
    10 Publications Verification

    		 FGFR Cancer
    BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 3 nM and a Kd of 6 nM. BLU9931 has significant antitumor activity .
    BLU9931
  • HY-101568
    Roblitinib
    5+ Cited Publications

    FGF-401

    		 FGFR Cancer
    Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM . Roblitinib has antitumor activity .
    Roblitinib
  • HY-156618
    Irpagratinib

    ABSK011

    		 FGFR Cancer
    Irpagratinib (ABSK011) is an orally active FGFR4 inhibitor (IC50<10 nM). Irpagratinib inhibits FGFR4 autophosphorylation and blocks signaling from FGFR4 to downstream pathway activation. Irpagratinib has shown high exposure in PK studies in mice, rats, and dogs, and also demonstrated antitumor activity in a subcutaneous xenograft tumor model .
    Irpagratinib
  • HY-100491
    H3B-6527

    		FGFR Cancer
    H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity .
    H3B-6527
  • HY-W005118
    2-Amino-4-fluoropyridine

    4-Fluoropyridin-2-amine

    		 Drug Intermediate Cancer
    2-Amino-4-fluoropyridine (4-Fluoropyridin-2-amine) is a drug intermediate that can be used for the synthesis reversible-covalent FGFR4 inhibitors .
    2-Amino-4-fluoropyridine
  • HY-147515
    FGFR4-IN-11

    		FGFR Cancer
    FGFR4-IN-11 (Compound 30) is a potent, selective, covalent FGFR4 inhibitor with an IC50 of 2.1 nM. FGFR4-IN-11 significantly inhibits the FGF19/FGFR4 signaling pathway and shows antitumor activity .
    FGFR4-IN-11
  • HY-161326
    CXF-007

    		FGFR Cancer
    CXF-007 is a potent and specific FGFR4 inhibitor with a IC50 value of 7 nM. CXF-007 has antitumor activity .
    CXF-007
  • HY-129181
    FGFR4-IN-4

    		FGFR Cancer
    FGFR4-IN-4 (compound 693) is a FGFR4 inhibitor with anti-tumor activity, extracted from patent WO2018113584A1 .
    FGFR4-IN-4
  • HY-161610
    FGFR4-IN-21

    		FGFR Cancer
    FGFR4-IN-21 (Compd 4c) is a FGFR4 inhibitor with an IC50 of 33 nM. FGFR4-IN-21 can be used for hepatocellular carcinoma research .
    FGFR4-IN-21
  • HY-174268
    FGFR-IN-21

    		FGFR Cancer
    FGFR-IN-21 (Compound FP1) is a selective covalent FGFR4 inhibitor with an IC50 value of 70 nM. FGFR-IN-21 is promising for research of FGFR signaling pathways in cancers .
    FGFR-IN-21
  • HY-160621
    CXF-009

    		FGFR Cancer
    CXF-009 is a selective and covalent FGFR4 inhibitor, with the IC50 of 48 nM. CXF-009 targeting Cys477 and Cys552 of FGFR4, and can be used for the study of hepatocellular carcinoma .
    CXF-009
  • HY-144759
    FGFR4-IN-9

    		FGFR Cancer
    FGFR4-IN-9 (Compound 6O) is a selective FGFR4 inhibitor with an IC50 of 75.3 nM. FGFR4-IN-9 effectively inhibits both the growth and angiogenesis of HCC .
    FGFR4-IN-9
  • HY-131704
    FGFR4-IN-5

    		FGFR Cancer
    FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research .
    FGFR4-IN-5
  • HY-172787
    FGFR4-IN-23

    		FGFR Akt AMPK Cancer
    FGFR4-IN-23 (compound 48c) is a FGFR4 inhibitor with an IC50 value of 2.9 nM against FGFR4 WT kinase. FGFR4-IN-23 inhibits the phosphorylation of FGFR4, AKT and MAPK .
    FGFR4-IN-23
  • HY-163569
    FGFR4-IN-20

    		FGFR Cancer
    FGFR4-IN-20 (comp 11) is an orally active and selective FGFR4 inhibitor with IC50s of 19 and 36 nM against Huh7 cells and FGFR4 enzyme. FGFR4-IN-20 can be used for hepatocellular carcinoma research .
    FGFR4-IN-20
  • HY-146541
    FGFR4-IN-10

    		FGFR Cancer
    FGFR4-IN-10 (compound 5a) is a potent and selective FGFR4 inhibitor with an IC50 value of 70.7 nM. FGFR4-IN-10 shows no inhibition against other FGFR family members, i.e. FGFR1, FGFR2 and FGFR3 .
    FGFR4-IN-10
  • HY-115902
    FGFR4-IN-7

    		FGFR Apoptosis Cancer
    FGFR4-IN-7 (Compound C3) is a covalent reversible FGFR4 inhibitor with an IC50 value of 0.42 μM. FGFR4-IN-7 induces apoptosis via the FGFR4 signaling pathway blockage. FGFR4-IN-7 can be used for the research of hepatocellular carcinoma (HCC) .
    FGFR4-IN-7
  • HY-158248
    FGFR4-IN-19

    		FGFR Cancer
    FGFR4-IN-19 (compound 8B) is a potent covalent fibroblast growth factor receptor 4 (FGFR4) inhibitor (IC50=1.2 nM). FGFR4-IN-19 achieves high efficiency and isotype selectivity by covalently targeting a rare cysteine (C552) in the FGFR4 kinase domain. FGFR4-IN-19 can be used for hepatocellular carcinoma (HCC) research .
    FGFR4-IN-19
  • HY-143881
    FGFR4-IN-6

    		FGFR Cancer
    FGFR4-IN-6 (Compound 9ka) is a covalently reversible FGFR4 inhibitor with an IC50 value of 5.4 nM. FGFR4-IN-6 also exhibits good oral pharmacokinetic properties. FGFR4-IN-6 induces significant tumor regressions in a xenograft mouse model of Hep3B2.1-7 HCC cell line without an obvious sign of toxicity . FGFR4-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    FGFR4-IN-6
  • HY-155046
    FGFR4-IN-14

    		FGFR Cancer
    FGFR4-IN-14 (Compound 27i) is a FGFR4 inhibitor (IC50: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC50s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC) .
    FGFR4-IN-14
  • HY-153502
    FGFR4-IN-13

    		FGFR Cancer
    FGFR4-IN-13 (Compound 6) is a selective FGFR4 inhibitor. FGFR4-IN-13 is applicable to the research of hepatocellular carcinoma .
    FGFR4-IN-13
  • HY-101568R
    Roblitinib (Standard)

    FGF-401 (Standard)

    		 FGFR Reference Standards Cancer
    Roblitinib (Standard) is the analytical standard of Roblitinib (HY-101568). This product is intended for research and analytical applications. Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM . Roblitinib has antitumor activity .
    Roblitinib (Standard)
  • HY-100492R
    Fisogatinib (Standard)

    BLU-554 (Standard)

    		 FGFR Reference Standards Cancer
    Fisogatinib (Standard) is the analytical standard of Fisogatinib (HY-100492). This product is intended for research and analytical applications. Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling .
    Fisogatinib (Standard)
  • HY-100491R
    H3B-6527 (Standard)

    		FGFR Reference Standards Cancer
    H3B-6527 (Standard) is the analytical standard of H3B-6527 (HY-100491). This product is intended for research and analytical applications. H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity .
    H3B-6527 (Standard)
  • HY-179381
    FGFR4-IN-24

    		FGFR Cancer
    FGFR4-IN-24 is a selective irreversible covalent FGFR4 inhibitor (IC50 = 1.2 nM). FGFR4-IN-24 shows much weaker activity against the other three FGFR family kinases (FGFR1-3). FGFR4-IN-24 inhibits the FGF19/FGFR4 signaling pathway, effectively suppressing the proliferation of the HuH-7 HCC cell line (GI50 = 17 nM). FGFR4-IN-24 exhibits significant antitumor activity in a HuH-7 mouse xenograft model. FGFR4-IN-24 can be used for the research of hepatocellular carcinoma .
    FGFR4-IN-24

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: